Navigation Links
ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
Date:2/9/2009

FREDERICK, Md., Feb. 9 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of their small molecule inhibitor of HIV-1 at the 16th CROI meeting held this week in Montreal. The presentation highlighted the advanced development of ImQuest's lead HIV pyrimidinedione inhibitor, IQP-0410. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription. The data presented demonstrate that IQP-0410 is well tolerated and safe with plasma drug concentrations 10-20-fold greater than those required for complete suppression of HIV replication at 24-hours following oral administration. Thus, IQP-0410 can be dosed once per day, and possesses a highly positive safety profile which suggests it will be amenable for use in women of child bearing years. Nick Kaludov, Ph.D., Director of Scientific Operations presented the new findings which also included metabolism, safety pharmacology, and genotoxicology evaluations. The studies included ImQuest co-authors Karen Watson, M.S. and Robert W. Buckheit, Jr., Ph.D.

"The data presented today indicate that IQP-0410 may represent a next generation HIV drug with a highly unique mechanism of action and an excellent safety profile," said Dr. Buckheit, Executive Vice President and Chief Scientific Officer. "We look forward to our upcoming clinical trial and believe that IQP-0410 will be an attractive new addition to existing antiretroviral therapies for HIV infection."

ImQuest recently submitted an Investigational New Drug application to the FDA to initiate human clinical trials with IQP-0410 and is concurrently developing a new generation pyrimidinedione with an enhanced barrier to resistance from among the series of pyrimidinediones.

ImQuest Life Sciences (www.ImquestLS.com<
'/>"/>

SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
3. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
(Date:9/17/2014)... 17, 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... that it has been granted a patent by ... its unique delivery system for delivering its "original" ... for the treatment of diseases with an inflammatory ...
(Date:9/17/2014)... FOREST, California , 17 de septiembre ... CYRX) ("la compañía"), principal proveedor mundial de ... de las ciencias de la vida, anunció ... compañía de logística global con sede en ... su base de clientes Europa en rápido ...
(Date:9/17/2014)... 17, 2014 Beckman Coulter , ... and healthcare, has renewed its agreement with Personify ... of the agreement, Personify will continue to streamline the ... on recruitment analytics, including time-to-fill, time-to-source and a deep ... agreement with Personify was based on the success of ...
Breaking Biology Technology:Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3
... sunlight at a modest cost is a challenge with ... paper in a special energy issue of Optics ... a relatively new approach to solar cells: lacing them ... the article, this approach has the potential to greatly ...
... GREENBELT, Md. - Engineers at the University of Idaho ... in upcoming NASA missions that will study the Earth ... of a grant technical officer Pen-Shu Yeh, a senior ... the engineering team at the University of ...
... Md. - Engineers at the University of Idaho have ... upcoming NASA missions that will study the Earth and ... a grant technical officer Pen-Shu Yeh, a senior engineer ... engineering team at the University of Idaho,s ...
Cached Biology Technology:Enhancing solar cells with nanoparticles 2New one-of-a-kind technology will fly on 2 NASA missions 2New one-of-a-kind technology will fly on 2 NASA missions 3New one-of-a-kind technology will fly on two NASA missions 2New one-of-a-kind technology will fly on two NASA missions 3
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
(Date:9/17/2014)... infections, including MRSA and MSSA could be curbed ... mimic the scaly surface of shark skin, according ... Antimicrobial Resistance and Infection Control . , ... the spread of human disease bacteria through touching, ... an arrangement of ridges formulated to resemble shark ...
(Date:9/16/2014)... Environmental Health at the Mailman School of Public Health ... asthma and prenatal exposure to two phthalates used in ... in the journal Environmental Health Perspectives . ... higher levels of the chemicals, butylbenzyl phthalate (BBzP) and ... percent increase in risk of developing asthma between age ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Sharks' skin has teeth in the fight against hospital superbugs 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... biomedical engineering at NJIT, has received a patent for a ... derivative of isosorbide and may be able to replace bisphenol ... lining of tin cans. Jaffe has been developing ... (ICPB) in an effort to promote and create new, commercially ...
... of Iowa study supports an earlier UI report that found ... Ship Canal (IHSC) in East Chicago, Ind. The study also ... of PCBs found in surrounding air and in Lake Michigan. ... journal Environmental Science and Technology (ES&T), a publication ...
... the immune system have identified a previously unrecognized set of ... The findings center on discovery of signaling molecules that are ... B cells to solid tumor growth. The most notable ... for more than decade to treat non-Hodgkin,s lymphoma, which is ...
Cached Biology News:NJIT patent may be able to replace BPA, make consumer products safer 2UI study measures levels of PCBs flowing from Indiana canal to air and water 2New cancer-fighting strategy focuses on signaling molecules 2New cancer-fighting strategy focuses on signaling molecules 3
The BD OptEIA Rat TNF-alpha ELISA Kit is for the quantitative determination of TNF-alpha in rat serum, plasma and cell culture supernatant....
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
...
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
Biology Products: